Drug intelligence / Profile preview

NH-102

Development stage: Phase 2
Lead developer: Jiangsu Nhwa Pharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

NH-102 is a small molecule drug in development for the treatment of major depressive disorder. It acts as an antagonist at the serotonin 2A (5-HT2A) receptor, and as an inhibitor of both the dopamine transporter (DAT) and norepinephrine transporter (NET). This multi-target mechanism suggests it modulates serotonergic, dopaminergic, and noradrenergic neurotransmission. The drug is being developed by Jiangsu Nhwa Pharmaceutical for oral administration. As of early 2025, NH-102 has reached Phase 2 clinical trials in China for major depressive disorder[1][2][4][5].

Targets

DAT (Dopamine plasma membrane transport protein)NET (Norepinephrine Transporter)HTR2A (Serotonin receptor 5-HT2A)

Beyond the preview

Go deeper on NH-102.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NH-102.

Explore the full profile